These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17008095)

  • 1. Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care.
    Uyl-de Groot CA
    Eur J Cancer; 2006 Nov; 42(17):2862-6. PubMed ID: 17008095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analyses of clinical trials in cancer: are they helpful to policy makers?
    Bennett CL; Armitage JL; LeSage S; Gulati SC; Armitage JO; Gorin NC
    Stem Cells; 1994 Jul; 12(4):424-9. PubMed ID: 7951008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodological issues in the economic analysis of cancer treatments.
    Tappenden P; Chilcott J; Ward S; Eggington S; Hind D; Hummel S
    Eur J Cancer; 2006 Nov; 42(17):2867-75. PubMed ID: 17023160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.
    Evans WK; Coyle D; Gafni A; Walker H;
    Chronic Dis Can; 2003; 24(4):102-7. PubMed ID: 14733759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medical-economic evaluation of lung cancers. Theoretical approaches and practical applications].
    Vergnenegre A; Chouaïd C; Lafuma A
    Rev Mal Respir; 1998 Sep; 15(4):469-78. PubMed ID: 9805757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methodology of economic assessment: example in oncology].
    Jaisson-Hot I; Schott AM; Clippe C; Ganne C; Hajri T; Poncet B; Trillet-Lenoir V; Colin C
    Bull Cancer; 2003 Nov; 90(11):939-45. PubMed ID: 14706896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analyses alongside randomised clinical trials.
    Gray AM
    Clin Trials; 2006; 3(6):538-42. PubMed ID: 17170038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and medical cost offset of psychosocial interventions in cancer care: making the case for economic analyses.
    Carlson LE; Bultz BD
    Psychooncology; 2004 Dec; 13(12):837-49; discussion 850-6. PubMed ID: 15578622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
    Hlubocky FJ; Ratain MJ; Wen M; Daugherty CK
    J Clin Oncol; 2007 Feb; 25(5):548-54. PubMed ID: 17290064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpreting the economic literature in oncology.
    Grusenmeyer PA; Wong YN
    J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presentation of economic evaluation results.
    Chaikledkaew U; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S66-73. PubMed ID: 19253489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.